Migraine Prophylaxis with Sodium Valproate

Introduction to Sodium Valproate

The American Academy of Family Physicians recommends sodium valproate as an effective first-line agent for migraine prevention, dosed at 800-1,500 mg per day, with strong efficacy in patients with prolonged or atypical migraine aura 1, 2
Sodium valproate is absolutely contraindicated in women of childbearing potential due to teratogenic risk, specifically neural tube defects 2

The American Academy of Family Physicians and the American College of Physicians establish sodium valproate as a first-line preventive agent alongside propranolol, timolol, and amitriptyline 1, 3, 4
The 2021 guidelines from the American Academy of Neurology classify sodium valproate as second-line therapy, reflecting concerns about teratogenicity rather than diminished efficacy 2, 5

The American Academy of Family Physicians recommends starting with 500 mg daily and titrating to 800-1,500 mg per day based on response and tolerability 1, 3
The American Academy of Neurology recommends 600-1,500 mg oral once daily 2
Initiate with a low dose and increase slowly to minimize adverse effects 1, 3

Sodium valproate is absolutely contraindicated in women of childbearing potential due to teratogenic effects, specifically neural tube defects 2
Liver disease is a contraindication 2
Thrombocytopenia is a contraindication 2

Hair loss, tremor, and weight gain are the most frequently reported adverse effects 1, 3

Initiate sodium valproate when patients have two or more migraine attacks per month producing disability lasting 3+ days per month 1, 3, 4
Use of acute rescue medication more than twice per week is an indication for preventive therapy 1, 3, 4
Failure of or contraindications to acute migraine treatments is an indication for preventive therapy 1, 3, 4
Presence of uncommon migraine conditions such as prolonged aura, migrainous infarction, or hemiplegic migraine is an indication for preventive therapy 1, 3, 4

The American Academy of Family Physicians and American College of Physicians establish valproic acid as a first-line preventive agent for migraine prophylaxis, with strong support from five controlled studies demonstrating efficacy 6, 7
Valproic acid is the more indicated agent for migraine prophylaxis, with strong evidence supporting its efficacy as a first-line preventive therapy, while levetiracetam lacks guideline support and has only modest evidence suggesting it may be comparable but not superior to established agents 6, 7

Levetiracetam is not mentioned in established migraine prophylaxis guidelines and lacks the evidence base required for first-line recommendation 6, 7
Valproic acid increases risk of grade 3-4 hematologic toxicities when combined with chemotherapy agents like temozolomide 8, 9, 10
Levetiracetam demonstrates better tolerability with fewer adverse drug reactions and higher retention rates compared to older anticonvulsants 8, 9, 10
Levetiracetam may be preferred when valproic acid is contraindicated due to its more favorable side effect profile 8, 9, 10

Monitor for thrombocytopenia and hepatotoxicity with valproic acid, particularly in patients on concurrent chemotherapy 8, 9, 10

Sodium valproate (including divalproex sodium) is supported by good evidence as an effective first‑line preventive therapy for migraine. The evidence originates from randomized controlled trials reported in Annals of Internal Medicine.[11][12]
The agents are especially beneficial for patients who experience prolonged or atypical migraine aura. This advantage is documented in the same trial series.[11][12]

The most frequently reported adverse effects of sodium valproate are weight gain, hair loss, and tremor; headache can also occur but is less common. These findings are derived from pooled safety data across multiple indications.[11][12]
When headache does emerge after initiating therapy, the therapeutic benefit for migraine prevention generally outweighs the risk of this treatment‑emergent symptom. This risk‑benefit assessment is based on the same evidence set.12

Serious adverse events associated with sodium valproate include liver disease, thrombocytopenia (observed in approximately 24 % of patients receiving high‑dose regimens), and weight gain. These safety signals are reported in the high‑dose subgroup analyses.12

All bullet points are supported by the cited references.